SEOVF (Sernova Biotherapeutics) Total Long-Term Assets: $0.01 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SEOVF Sernova Biotherapeutics Inc SEOVF
32 GF Score
Price $0.08
! 2 Warning Signs
View Full Analysis

What is Sernova Biotherapeutics Total Long-Term Assets?

Sernova Biotherapeutics SEOVF +5.66% 32 Total Long-Term Assets is $0.01 Mil as of Apr. 2026. GuruFocus rates SEOVF with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Sernova Biotherapeutics's Total Long-Term Assets for the quarter that ended in Apr. 2026 was $0.01 Mil.

Sernova Biotherapeutics Total Long-Term Assets Related Terms

Sernova Biotherapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Sernova Biotherapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sernova Biotherapeutics Total Long-Term Assets Chart

Sernova Biotherapeutics Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.20 1.02 0.79 0.77 0.17

Sernova Biotherapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.30 0.17 0.17 0.01
SEOVF
32GF Score
Sernova Biotherapeutics Inc SEOVF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sernova Biotherapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $0.01 Mil mean?
Sernova Biotherapeutics (SEOVF) has a Total Long-Term Assets of $0.01 Mil as of Apr. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Sernova Biotherapeutics and its competitors.
Is Sernova Biotherapeutics' Total Long-Term Assets too high?
Sernova Biotherapeutics' current Total Long-Term Assets is $0.01 Mil. Overall, Sernova Biotherapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Sernova Biotherapeutics' Total Long-Term Assets compare to VRTX and REGN?
Sernova Biotherapeutics' Total Long-Term Assets of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Sernova Biotherapeutics and its competitors. Sernova Biotherapeutics's current Total Long-Term Assets is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sernova Biotherapeutics stock overvalued right now?
Sernova Biotherapeutics (SEOVF) has a current Total Long-Term Assets of $0.01 Mil. The current Total Long-Term Assets is $0.01 Mil. Sernova Biotherapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Sernova Biotherapeutics (SEOVF), the current Total Long-Term Assets is $0.01 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sernova Biotherapeutics Business Description

Other Exchanges PSH0:GermanySVA:Canada
Address RPO Central Parkway, PO Box 29592, Mississauga, ON, CAN, L5A 4H2
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
32GF Score

Get the complete analysis for SEOVF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price